Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

494

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide twice daily (BID)

subcutaneous injection (5 mcg or 10 mcg), twice a day

DRUG

premixed insulin aspart twice daily (BID)

subcutaneous injection (titrated appropriately), twice a day

Trial Locations (39)

Unknown

Research Site, Bad Mergentheim

Research Site, Berlin

Research Site, Bosenheim

Research Site, Burghausen

Research Site, Datteln

Research Site, Dresden

Research Site, Essen

Research Site, Friedrichsthal

Research Site, Hildesheim

Research Site, Hirschhorn

Research Site, Hohenmölsen

Research Site, Jena

Research Site, Lehrte

Research Site, Leipzig

Research Site, Ludwigsburg

Research Site, Mannheim

Research Site, Marburg

Research Site, Marktheidenfeld

Research Site, Meissen

Research Site, München

Research Site, Offenbach

Research Site, Oschatz

Research Site, Pohlheim

Research Site, Regensburg

Research Site, Riesa

Research Site, Rodgau

Research Site, Roding

Research Site, Rosenheim

Research Site, Schlüchtern

Research Site, Schwedt

Research Site, Sinsheim

Research Site, Speyer

Research Site, Unterhaching

Research Site, Völklingen

Research Site, Wallerfing

Research Site, Wangen

Research Site, Warburg

Research Site, Wiesbaden

Research Site, Wolfsburg

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY